Literature DB >> 21282485

Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanoma.

Mario Mandalà1, Gian Lorenzo Imberti, Dario Piazzalunga, Maurizio Belfiglio, Giuseppe Lucisano, Roberto Labianca, Lorenzo Marchesi, Barbara Merelli, Silvana Robone, Paola Poletti, Laura Milesi, Carlo Tondini.   

Abstract

OBJECTIVE: To investigate the influence of socioeconomic status (SES) on Breslow thickness, disease-free survival, and overall survival in patients with stage I-II primary cutaneous melanoma (PCM). PATIENTS AND METHODS: The study consists of all consecutive patients who were diagnosed as having PCM and were treated and followed up at our hospital between November 1, 1998, and July 31, 2009. Pathologic and sociodemographic characteristics of the patients were obtained. We categorized SES into 3 levels: low (manual employees and skilled/unskilled workers, including farmers, with primary education level), middle (nonmanual employees and clerks with middle education level), and high (professionals, executives, administrators, and entrepreneurs with tertiary education).
RESULTS: A total of 1443 consecutive patients were evaluated. In a multivariate logistic regression analysis, sex (female vs male: odds ratio [OR], 1.37; 95% confidence interval [CI], 1.08-1.75), SES (high vs middle: OR, 1.27; 95% CI, 0.96-1.69; high vs low: OR, 1.73; 95% CI, 1.26-2.38), age (<60 vs ≥60 years: OR, 1.35; 95% CI, 1.03-1.78), and family context (single vs living with relatives: OR, 1.37; 95% CI, 0.97-1.94) were the strongest correlates of Breslow thickness. Compared with high SES, the risk of melanoma-related death, adjusted for age and sex, was 7 times higher (hazard ratio, 7.44; 95% CI, 3.27-16.93) and almost 2 times higher (hazard ratio, 1.88; 95% CI, 1.04-3.39) in patients with low SES living alone or living with relatives, respectively.
CONCLUSION: In patients with PCM, low SES is associated with thicker melanoma and a poorer clinical outcome.

Entities:  

Mesh:

Year:  2011        PMID: 21282485      PMCID: PMC3031435          DOI: 10.4065/mcp.2010.0671

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  22 in total

1.  Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status.

Authors:  R M MacKie; D J Hole
Journal:  BMJ       Date:  1996-05-04

2.  Tree-structured prediction for censored survival data and the Cox model.

Authors:  A Ciampi; A Negassa; Z Lou
Journal:  J Clin Epidemiol       Date:  1995-05       Impact factor: 6.437

3.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

4.  Racial/ethnic patterns of care for cancers of the oral cavity, pharynx, larynx, sinuses, and salivary glands.

Authors:  Vickie L Shavers; Linda C Harlan; Deborah Winn; William W Davis
Journal:  Cancer Metastasis Rev       Date:  2003-03       Impact factor: 9.264

5.  Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system.

Authors:  S A Optenberg; I M Thompson; P Friedrichs; B Wojcik; C R Stein; B Kramer
Journal:  JAMA       Date:  1995 Nov 22-29       Impact factor: 56.272

6.  Socioeconomic factors, health behaviors, and mortality: results from a nationally representative prospective study of US adults.

Authors:  P M Lantz; J S House; J M Lepkowski; D R Williams; R P Mero; J Chen
Journal:  JAMA       Date:  1998-06-03       Impact factor: 56.272

7.  Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis.

Authors:  Elisabetta Rapiti; Gerald Fioretta; Robin Schaffar; Isabel Neyroud-Caspar; Helena M Verkooijen; Franz Schmidlin; Raymond Miralbell; Roberto Zanetti; Christine Bouchardy
Journal:  Cancer       Date:  2009-12-01       Impact factor: 6.860

8.  Age as a prognostic factor in the malignant melanoma population.

Authors:  P F Austin; C W Cruse; G Lyman; K Schroer; F Glass; D S Reintgen
Journal:  Ann Surg Oncol       Date:  1994-11       Impact factor: 5.344

9.  Cutaneous melanoma mortality among the socioeconomically disadvantaged in Massachusetts.

Authors:  A C Geller; D R Miller; R A Lew; R W Clapp; M B Wenneker; H K Koh
Journal:  Am J Public Health       Date:  1996-04       Impact factor: 9.308

10.  Differences in breast cancer stage, treatment, and survival by race and ethnicity.

Authors:  Christopher I Li; Kathleen E Malone; Janet R Daling
Journal:  Arch Intern Med       Date:  2003-01-13
View more
  14 in total

1.  The influence of dermatologist and primary care physician visits on melanoma outcomes among Medicare beneficiaries.

Authors:  Richard G Roetzheim; Ji-Hyun Lee; Jeanne M Ferrante; Eduardo C Gonzalez; Ren Chen; Kate J Fisher; Kymia Love-Jackson; Ellen P McCarthy
Journal:  J Am Board Fam Med       Date:  2013 Nov-Dec       Impact factor: 2.657

2.  Sun exposure and melanoma survival: a GEM study.

Authors:  Marianne Berwick; Anne S Reiner; Susan Paine; Bruce K Armstrong; Anne Kricker; Chris Goumas; Anne E Cust; Nancy E Thomas; Pamela A Groben; Lynn From; Klaus Busam; Irene Orlow; Loraine D Marrett; Richard P Gallagher; Stephen B Gruber; Hoda Anton-Culver; Stefano Rosso; Roberto Zanetti; Peter A Kanetsky; Terry Dwyer; Alison Venn; Julia Lee-Taylor; Colin B Begg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-28       Impact factor: 4.254

3.  Melanoma in women of childbearing age and in pregnancy in California, 1994-2015: a population-based cohort study.

Authors:  M Kiuru; Q Li; G Zhu; J R Terrell; K Beroukhim; E Maverakis; T H M Keegan
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-08-23       Impact factor: 9.228

4.  The association between socioeconomic status and the symptoms at diagnosis of celiac disease: a retrospective cohort study.

Authors:  Abhik Roy; Shilpa Mehra; Ciarán P Kelly; Sohaib Tariq; Kumar Pallav; Melinda Dennis; Ann Peer; Benjamin Lebwohl; Peter H R Green; Daniel A Leffler
Journal:  Therap Adv Gastroenterol       Date:  2016-03-18       Impact factor: 4.409

5.  Host Characteristics and Risk of Incident Melanoma by Breslow Thickness.

Authors:  Wen-Qing Li; Eunyoung Cho; Shaowei Wu; Suyun Li; Natalie H Matthews; Abrar A Qureshi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-19       Impact factor: 4.254

6.  Survival of sentinel node biopsy versus observation in intermediate-thickness melanoma: A Dutch population-based study.

Authors:  R M H Roumen; M S Schuurman; M J Aarts; A J G Maaskant-Braat; G Vreugdenhil; W J Louwman
Journal:  PLoS One       Date:  2021-05-25       Impact factor: 3.240

7.  Late-Stage Melanoma: Be Sure to Screen Uninsured, Unmarried Men.

Authors:  Virginia L Valentin; Wayne Sanderson; Susan Westneat; Eric Durbin
Journal:  South Med J       Date:  2018-11       Impact factor: 0.810

8.  Predictors of skin self-examination before and after a melanoma diagnosis: the role of medical advice and patient's level of education.

Authors:  Annett Körner; Adina Coroiu; Claudia Martins; Beatrice Wang
Journal:  Int Arch Med       Date:  2013-02-27

9.  Sunny holidays before and after melanoma diagnosis are respectively associated with lower Breslow thickness and lower relapse rates in Italy.

Authors:  Sara Gandini; Esther De Vries; Giulio Tosti; Edoardo Botteri; Giuseppe Spadola; Patrick Maisonneuve; Chiara Martinoli; Arjen Joosse; Pier Francesco Ferrucci; Federica Baldini; Emilia Cocorocchio; Elisabetta Pennacchioli; Francesco Cataldo; Barbara Bazolli; Alessandra Clerici; Massimo Barberis; Veronique Bataille; Alessandro Testori
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

10.  Sun exposure and melanoma prognostic factors.

Authors:  Sara Gandini; Maurizio Montella; Fabrizio Ayala; Lucia Benedetto; Carlo Riccardo Rossi; Antonella Vecchiato; Maria Teresa Corradin; Vincenzo DE Giorgi; Paola Queirolo; Guido Zannetti; Giuseppe Giudice; Giovanni Borroni; Rosachiara Forcignanò; Ketty Peris; Giulio Tosti; Alessandro Testori; Giusto Trevisan; Francesco Spagnolo; Paolo A Ascierto
Journal:  Oncol Lett       Date:  2016-03-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.